Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.

BACKGROUND:Malawi introduced pneumococcal conjugate vaccine (PCV13) and monovalent rotavirus vaccine (RV1) in 2011 and 2012 respectively, and is planning the introduction of a second-dose measles vaccine (MV). We assessed predictors of availability, uptake and timeliness of these vaccines in a rural...

Full description

Bibliographic Details
Main Authors: Hazzie Mvula, Ellen Heinsbroek, Menard Chihana, Amelia C Crampin, Storn Kabuluzi, Geoffrey Chirwa, Charles Mwansambo, Anthony Costello, Nigel A Cunliffe, Robert S Heyderman, Neil French, Naor Bar-Zeev, VacSurv Consortium
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4859501?pdf=render
id doaj-0b14d20169e540099402da0154dd1137
record_format Article
spelling doaj-0b14d20169e540099402da0154dd11372020-11-25T02:47:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01115e015499710.1371/journal.pone.0154997Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.Hazzie MvulaEllen HeinsbroekMenard ChihanaAmelia C CrampinStorn KabuluziGeoffrey ChirwaCharles MwansamboAnthony CostelloNigel A CunliffeRobert S HeydermanNeil FrenchNaor Bar-ZeevVacSurv ConsortiumBACKGROUND:Malawi introduced pneumococcal conjugate vaccine (PCV13) and monovalent rotavirus vaccine (RV1) in 2011 and 2012 respectively, and is planning the introduction of a second-dose measles vaccine (MV). We assessed predictors of availability, uptake and timeliness of these vaccines in a rural Malawian setting. METHODS:Commencing on the first date of PCV13 eligibility we conducted a prospective population-based birth cohort study of 2,616 children under demographic surveillance in Karonga District, northern Malawi who were eligible for PCV13, or from the date of RV1 introduction both PCV13 and RV1. Potential predictors of vaccine uptake and timeliness for PCV13, RV1 and MV were analysed respectively using robust Poisson and Cox regression. RESULTS:Vaccine coverage was high for all vaccines, ranging from 86.9% for RV1 dose 2 to 95.4% for PCV13 dose 1. Median time delay for PCV13 dose 1 was 17 days (IQR 7-36), 19 days (IQR 8-36) for RV1 dose 1 and 20 days (IQR 3-46) for MV. Infants born to lower educated or farming mothers and those living further away from the road or clinic were at greater risk of being not fully vaccinated and being vaccinated late. Delays in vaccination were also associated with non-facility birth. Vaccine stock-outs resulted in both a delay in vaccine timeliness and in a decrease in completion of schedule. CONCLUSION:Despite high vaccination coverage in this setting, delays in vaccination were common. We identified programmatic and socio-demographic risk factors for uptake and timeliness of vaccination. Understanding who remains most vulnerable to be unvaccinated allows for focussed delivery thereby increasing population coverage and maximising the equitable benefits of universal vaccination programmes.http://europepmc.org/articles/PMC4859501?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Hazzie Mvula
Ellen Heinsbroek
Menard Chihana
Amelia C Crampin
Storn Kabuluzi
Geoffrey Chirwa
Charles Mwansambo
Anthony Costello
Nigel A Cunliffe
Robert S Heyderman
Neil French
Naor Bar-Zeev
VacSurv Consortium
spellingShingle Hazzie Mvula
Ellen Heinsbroek
Menard Chihana
Amelia C Crampin
Storn Kabuluzi
Geoffrey Chirwa
Charles Mwansambo
Anthony Costello
Nigel A Cunliffe
Robert S Heyderman
Neil French
Naor Bar-Zeev
VacSurv Consortium
Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.
PLoS ONE
author_facet Hazzie Mvula
Ellen Heinsbroek
Menard Chihana
Amelia C Crampin
Storn Kabuluzi
Geoffrey Chirwa
Charles Mwansambo
Anthony Costello
Nigel A Cunliffe
Robert S Heyderman
Neil French
Naor Bar-Zeev
VacSurv Consortium
author_sort Hazzie Mvula
title Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.
title_short Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.
title_full Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.
title_fullStr Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.
title_full_unstemmed Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study.
title_sort predictors of uptake and timeliness of newly introduced pneumococcal and rotavirus vaccines, and of measles vaccine in rural malawi: a population cohort study.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description BACKGROUND:Malawi introduced pneumococcal conjugate vaccine (PCV13) and monovalent rotavirus vaccine (RV1) in 2011 and 2012 respectively, and is planning the introduction of a second-dose measles vaccine (MV). We assessed predictors of availability, uptake and timeliness of these vaccines in a rural Malawian setting. METHODS:Commencing on the first date of PCV13 eligibility we conducted a prospective population-based birth cohort study of 2,616 children under demographic surveillance in Karonga District, northern Malawi who were eligible for PCV13, or from the date of RV1 introduction both PCV13 and RV1. Potential predictors of vaccine uptake and timeliness for PCV13, RV1 and MV were analysed respectively using robust Poisson and Cox regression. RESULTS:Vaccine coverage was high for all vaccines, ranging from 86.9% for RV1 dose 2 to 95.4% for PCV13 dose 1. Median time delay for PCV13 dose 1 was 17 days (IQR 7-36), 19 days (IQR 8-36) for RV1 dose 1 and 20 days (IQR 3-46) for MV. Infants born to lower educated or farming mothers and those living further away from the road or clinic were at greater risk of being not fully vaccinated and being vaccinated late. Delays in vaccination were also associated with non-facility birth. Vaccine stock-outs resulted in both a delay in vaccine timeliness and in a decrease in completion of schedule. CONCLUSION:Despite high vaccination coverage in this setting, delays in vaccination were common. We identified programmatic and socio-demographic risk factors for uptake and timeliness of vaccination. Understanding who remains most vulnerable to be unvaccinated allows for focussed delivery thereby increasing population coverage and maximising the equitable benefits of universal vaccination programmes.
url http://europepmc.org/articles/PMC4859501?pdf=render
work_keys_str_mv AT hazziemvula predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT ellenheinsbroek predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT menardchihana predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT ameliaccrampin predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT stornkabuluzi predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT geoffreychirwa predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT charlesmwansambo predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT anthonycostello predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT nigelacunliffe predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT robertsheyderman predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT neilfrench predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT naorbarzeev predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
AT vacsurvconsortium predictorsofuptakeandtimelinessofnewlyintroducedpneumococcalandrotavirusvaccinesandofmeaslesvaccineinruralmalawiapopulationcohortstudy
_version_ 1724755099155169280